

Published in final edited form as:

Medchemcomm. 2014 August 1; 5(8): 1126–1129. doi:10.1039/C4MD00103F.

Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines†

Qian Qin, Zhaojun Yin, Philip Bentley, and Xuefei Huang

Department of Chemistry, Michigan State University, Chemistry Building, Room 426, 578 S. Shaw Lane, East Lansing, MI 48824, USA

Xuefei Huang: xuefei@chemistry.msu.edu

Abstract

Tumor associated carbohydrate antigens (TACAs) are overexpressed on tumor cells, which renders them attractive targets for anti-cancer vaccines. To overcome the poor immunogenicity of TACAs, we designed a polymer platform for antigen presentation by co-delivering TACA and helper T (Th) cell epitope on the same chain. The block copolymer was synthesized by cyanoxyl-mediated free radical polymerization followed by conjugation with a TACA Tn antigen and a mouse Th-cell peptide epitope derived from polio virus (PV) to afford the vaccine construct. The glycopolymer vaccine elicited an anti-Tn immune response with significant titers of IgG antibodies, which recognized Tn-expressing tumor cells.

Introduction

The stimulation of immune systems through the use of a construct that can elicit a specific immune response against cancer is the basis of anti-cancer vaccines.¹ Cancer cells often bear characteristic carbohydrate structures on their cell surface.^{2,3} These tumor associated carbohydrate antigens (TACAs) are shared by a variety of cancer cell types, which make them attractive for anti-cancer vaccine development.^{4–11} However, serious challenges exist in order to elicit powerful anti-TACA immunity. Direct vaccination with TACA alone typically can only induce weak activation of antibody secreting B cells with no cooperation from Th cells.¹² As a result, the antibodies secreted are mainly the low affinity IgM type. Since T cells typically recognize peptide epitopes, conjugating TACA to a Th cell peptide epitope should allow the stimulation of both B cells and Th cells. The matched Th cells provide stimulatory signals that can induce the B cells to undergo isotype switching leading to high affinity IgG antibodies.¹³ Many innovative carriers have been developed to co-deliver TACAs with Th epitopes. The most common type of carrier is immunogenic proteins such as keyhole limpet haemocyanin,^{14–17} tetanus toxoid,^{18,19} and *Bacillus Calmette–Guerin*.²⁰ Other antigen presenting platforms include dendrimers,^{21,22} regioselectively

†Electronic supplementary information (ESI) available: Full experimental details including: chemical synthesis, NMR spectra and immunological analysis. See DOI: 10.1039/c4md00103f

addressable functionalized templates,²³ nanomaterials,^{24,25} liposomes and proteoliposomes^{26,27} polysaccharides²⁸ and virus-like particles.^{29,30}

Polymers are a class of synthetic carrier that has multiple potential advantages for TACA delivery. A polymer chain can carry many TACA molecules, which can enhance the avidities between the antigen and B cell receptors (BCRs) through the polyvalency effect and lead to strong activation of B cells. Furthermore, Th epitopes can be introduced into the glycopolymer to potentiate Th cells generating a long lasting humoral immune response. Although synthetic glycopolymers have been utilized in a variety of applications^{31,32} including biosensing,³³ delivery of therapeutic,^{34,35} modulation of natural killer cell function³⁶ and cellular signaling,³⁷ it is only recently that they have been explored as a TACA carrier.^{38,39} Herein, we present our results on using water soluble block copolymers as a platform to codeliver TACA and a Th epitope as a potential anti-cancer vaccine.

Results and discussion

We selected the cyanoxyl-mediated free radical polymerization method^{40–43} for polymer construction due to the mild reaction condition. In order to incorporate both TACAs and Th epitope, the copolymer was designed to contain a block with multiple ammonium moieties followed by a methyl ester block (see polymer **7** in Scheme 1). The polymerization was initiated by the treatment of aniline **1** with sodium nitrite and fluoroboric acid, which was followed by the addition of a mixture of sodium cyanate, acrylamide **3** and methacrylamide amine **4** and heating at 50 °C for 40 hours leading to intermediate polymer **5** (Scheme 1). Subsequently, acrylamide **3** and acrylamide methyl ester monomer **6** were added to the reaction mixture with further heating for another 40 hours. The resulting mixture was dialyzed in water to obtain copolymer **7** in 50% yield. Based on integrations of ¹H-NMR peaks from the polymers using the aromatic peaks from the terminal phenyl ring as the internal standard, there were on average 45 ammonium ion and 4 of methyl esters per polymer chain of **7**. Gel permeation chromatography analysis showed that polymer **7** has a molecular weight (Mn) of 13 800 with a polydispersity index of 1.14.

To test the efficiency of TACA delivery, a representative TACA, *i.e.*, the Tn antigen was introduced into the polymer. The Tn antigen, found over-expressed on a variety of cancer cell surface including 90% of breast cancer carcinoma, is an appealing target for TACA based anti-cancer vaccine development.^{44–46} A flexible amide linker was designed to conjugate Tn with the polymer to avoid potential humoral responses to the linker.⁴⁷ In order to accomplish this, Tn derivative **8** in the form of *N*-hydroxysuccinimide (NHS) activated ester was synthesized⁴⁸ and linked with the amines in polymer **7** promoted by *N,N*-diisopropyl ethyl amine (DIPEA) leading to glycopolymer **9** in 65% yield (Scheme 2). On average, 31 copies of Tn were introduced per chain based on ¹H-NMR analysis. Polymer **9** was then treated with LiOH to hydrolyze all the methyl esters, which was supported by ¹H-NMR analysis showing the complete disappearance of the methyl groups. The resulting polymer was functionalized with pyridyl disulfide **10**, which then reacted with a cysteine modified oligopeptide from polio virus (PV) to introduce the helper T cell epitope^{26,49} through the formation of disulfide bonds. The number of PV peptide per glycopolymer **13** was determined to be 2 peptides per chain by cleaving the disulfide linkage between the

peptide and the glycopolymer followed by HPLC quantification. As a control, polymer **14** was synthesized by capping the amine groups of polymer **7** with methoxyacetic acid, which was followed by introduction of two PV peptides per chain utilizing a similar protocol as in the construction of polymer **13**.

With the peptidic glyco-copolymer **13** in hand, its ability to elicit antibodies was evaluated. Mice were injected with glyco-polymer **13** (4 μ g Tn per dose) subcutaneously with Freund's adjuvant (CFA) followed by two booster injections at intervals of two weeks (days 14 and 28). Sera were drawn from mice one week after the final injection (day 35). The control group was vaccinated with polymer **14** following an identical protocol. To test anti-Tn antibody levels in sera, enzyme linked immunosorbent assay (ELISA) was performed using Tn functionalized bovine serum albumin (BSA) immobilized on microtiter plates. Analysis showed that the main antibodies induced by **13** were the IgG type with an IgG titer of 4432 (Fig. 1a. For IgM titers, see Fig. S2[†]). In comparison, the sera from mice receiving control polymer **14** contained extremely low titers of anti-Tn IgG antibodies (mean titer = 100) (Fig. 1a). The fact that high titers of IgG antibodies were induced by **13** implies the Tn-specific B cells have undergone isotype switching. Another important characteristic of a successful vaccine is the maintenance of immune responses. To evaluate this, mice immunized with **13** were bled on day 89. ELISA analysis showed that the anti-Tn IgG titers remained at a similar level (Fig. 1a, mean titer = 4369) suggesting long lasting humoral immunity was generated.

For many TACA constructs with highly immunogenic protein carriers, antibodies specific against the carrier are induced as well, the titers of which can be hundreds times higher than that against the desired TACA.^{47,50} The strong anti-carrier responses can potentially interfere with the generation of glycan specific antibodies due to antigen competition.^{51–53} The antibodies generated against the polymer backbone were analyzed. As shown in Fig. 1b, immunization with glycopolymer **13** or control polymer **14** elicited similar amounts of anti-polymer IgG antibodies with titers around 700 as compared to a titer of 400 pre-immunization. The relatively low anti-polymer titers induced suggest the polymer backbone most likely does not compete significantly for B cell interactions.

As ELISA tests antibody binding to an artificial BSA–Tn construct, it is important to determine whether the antibodies elicited can recognize Tn expressed in its native environment, *i.e.*, cancer cells. Jurkat cells are known to express large amounts of Tn antigen on their surfaces.⁵⁴ The post-immune serum from mice immunized with glycopolymer **13** exhibited significant binding with Jurkat cells, while those from the control polymer did not react with the cells (Fig. 1c).

In conclusion, a fully synthetic glycopolymer vaccine incorporating multiple Tn antigen and Th cell peptide epitope has been prepared, which elicited significant and long-lasting anti-Tn IgG antibody titers. The antibodies recognized Tn antigens on tumor cells. Compared with other delivery platforms such as virus like particles,^{29,30,48} the anti-Tn antibody titers generated by the glycopolymer constructs were modest. However, the polymer platform offers great flexibilities to adjust antigen densities and valency as well as the ratio of TACA vs. Th epitope. In addition, the immunogenicity of the polymer backbone is not high, which

likely will not compete significantly with the desired TACA for B cell activation. These attributes bode well for further optimization of the glycopolymer construct to enhance the humoral responses against the TACAs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to the National Cancer Institute for generous financial support of our work (R01CA149451).

References

1. Finn OJ. *Nat Rev Immunol.* 2003; 3:630. [PubMed: 12974478]
2. Hakomori S. *Adv Exp Med Biol.* 2001; 491:369. [PubMed: 14533809]
3. Hakomori S, Zhang Y. *Chem Biol.* 1997; 4:97. [PubMed: 9190292]
4. Liu CC, Ye XS. *Glycoconjugate J.* 2012; 29:259.
5. Yin Z, Huang X. *J Carbohydr Chem.* 2012; 31:143. [PubMed: 22468019]
6. Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse-Olson K. *Vaccine.* 2011; 29:8802. [PubMed: 21964054]
7. Morelli L, Poletti L, Lay L. *Eur J Org Chem.* 2011; 2011:5723.
8. Zhu JL, Warren JD, Danishefsky SJ. *Expert Rev Vaccines.* 2009; 8:1399. [PubMed: 19803761]
9. Guo ZW, Wang QL. *Curr Opin Chem Biol.* 2009; 13:608. [PubMed: 19766052]
10. Freire T, Bay S, Vichier-Guerre S, Lo-Man R, Leclerc C. *Mini-Rev Med Chem.* 2006; 6:1357. [PubMed: 17168812]
11. Kuberan B, Linhardt RJ. *Curr Org Chem.* 2000; 4:653.
12. Mond JJ, Lees A, Snapper CM. *Annu Rev Immunol.* 1995; 13:655. [PubMed: 7612238]
13. Goldsby, RA.; Kindt, TJ.; Osborne, BA. *Kuby Immunology.* 4. W. H. Freeman and Company; New York: 2000. p. 461
14. Holmberg, LA.; Guthrie, KA.; Sandmaier, BM. *Chemical Glycobiology (ACS Symposium Series, 990).* Chen, X.; Halcomb, RL.; Wang, PG., editors. Washington, D. C: 2008. p. 197
15. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansiehsky SJ, Livingston PO. *Clin Cancer Res.* 2007; 13:4170. [PubMed: 17634545]
16. Danishefsky SJ, Allen JR. *Angew Chem, Int Ed.* 2000; 39:836.
17. Helling FS, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HE, Livingston PO. *Cancer Res.* 1994; 54:197. [PubMed: 8261439]
18. Hoffmann-Roder A, Kaiser A, Wagner S, Gaidzik N, Kowalczyk D, Westerlind U, Gerlitzki B, Schmitt E, Kunz H. *Angew Chem, Int Ed.* 2010; 49:8498.
19. Rich JR, Wakarchuk WW, Bundle DR. *Chem– Eur J.* 2006; 12:845. [PubMed: 16196067]
20. Livingston POW, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ. *J Clin Oncol.* 1994; 12:1036. [PubMed: 8164027]
21. Heegaard PMH, Boas U, Sorensen NS. *Bioconjugate Chem.* 2010; 21:405.
22. Lo-Man R, Vichier-Guerre S, Perraut R, Deriaud E, Huteau V, BenMohamed L, Diop OM, Livingston PO, Bay S, Leclerc C. *Cancer Res.* 2004; 64:4987. [PubMed: 15256473]
23. Grigalevicius S, Chierici S, Renaudet O, Lo-Man R, Deriaud E, Leclerc C, Dumy P. *Bioconjugate Chem.* 2005; 16:1149.
24. Brinas RP, Sundgren A, Sahoo P, Morey S, Rittenhouse-Olson K, Wilding GE, Deng W, Barchi JJ. *Bioconjugate Chem.* 2012; 23:1513.

25. Ojeda R, de Paz JL, Barrientos AG, Martin-Lomas M, Penades S. *Carbohydr Res.* 2007; 342:448. [PubMed: 17173881]
26. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, Madsen CS, Cohen PA, Gendler SJ, Boons GJ. *Proc Natl Acad Sci U S A.* 2012; 109:261. [PubMed: 22171012]
27. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM. *Expert Rev Vaccines.* 2003; 2:817. [PubMed: 14711364]
28. De Silva RA, Wang Q, Chidley T, Appulage DK, Andreana PR. *J Am Chem Soc.* 2009; 131:9622. [PubMed: 19552408]
29. Yin Z, Nguyen HG, Chowdhury S, Bentley P, Bruckman MA, Miermont A, Gildersleeve JC, Wang Q, Huang X. *Bioconjugate Chem.* 2012; 23:1694.
30. Miermont A, Barnhill H, Strable E, Lu XW, Wall KA, Wang Q, Finn MG, Huang X. *Chem– Eur J.* 2008; 14:4939. [PubMed: 18431733]
31. Narla SN, Nie H, Li Y, Sun XL. *J Carbohydr Chem.* 2012; 31:67.
32. Narain, R. *Engineered Carbohydrate-Based Materials for Biomedical Applications: Polymers, Surfaces, Dendrimers, Nanoparticles, and Hydrogels.* John Wiley & Sons, Inc; 2011.
33. Sun XL, Faucher KM, Houston M, Grande D, Chaikof EL. *J Am Chem Soc.* 2002; 124:7258. [PubMed: 12071720]
34. Suriano F, Pratt R, Tan JPK, Wiradharma N, Nelson A, Yang YY, Dubois P, Hedrick JL. *Biomaterials.* 2010; 31:2637. [PubMed: 20074794]
35. Kim B, Peppas NA. *J Biomater Sci Polymer Ed.* 2002; 13:1271.
36. Hudak JE, Canham SM, Bertozzi CR. *Nat Chem Biol.* 2013; 10:69. [PubMed: 24292068]
37. Wu L, Sampson NS. *ACS Chem Biol.* 2014; 9:468. [PubMed: 24252131]
38. Parry AL, Clemson NA, Ellis J, Bernhard SSR, Davis BG, Cameron NR. *J Am Chem Soc.* 2013; 135:9362. [PubMed: 23763610]
39. Nuhn L, Hartmann S, Palitzsch B, Gerlitzki B, Schmitt E, Zentel R, Kunz H. *Angew Chem, Int Ed.* 2013; 52:10652.
40. Sun XL, Grande D, Baskaran C, Hanson SR, Chaikof EL. *Biomacromolecules.* 2002; 3:1065. [PubMed: 12217054]
41. Baskaran S, Grande D, Sun XL, Yayon A, Chaikof EL. *Bioconjugate Chem.* 2002; 13:1309.
42. Grande D, Baskaran S, Chaikof EL. *Macromolecules.* 2001; 34:1640.
43. Grande D, Baskaran S, Baskaran C, Gnanou Y, Chaikof EL. *Macromolecules.* 2000; 33:1123.
44. Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. *Breast Canc Res.* 2010; 12:204.
45. Li Q, Anver MR, Butcher DO, Gildersleeve JC. *Mol Cancer Ther.* 2009; 8:971. [PubMed: 19372570]
46. Springer GF. *Science.* 1984; 224:1198. [PubMed: 6729450]
47. Buskas T, Li Y, Boons GJ. *Chem– Eur J.* 2004; 10:3517. [PubMed: 15252797]
48. Yin Z, Comellas-Aragones M, Chowdhury S, Bentley P, Kaczanowska K, BenMohamed L, Gildersleeve JC, Finn MG, Huang X. *ACS Chem Biol.* 2013; 8:1253. [PubMed: 23505965]
49. Leclerc C, Deriaud E, Mimic V, van der Werf S. *J Virol.* 1991; 65:711. [PubMed: 1702841]
50. Deng K, Adams MM, Damani P, Livingston PO, Ragupathi G, Gin DY. *Angew Chem, Int Ed.* 2008; 47:6395.
51. Sad S, Gupta HM, Talwar GP, Raghupathy R. *Immunology.* 1991; 74:223. [PubMed: 1748470]
52. Di John D, Wasserman SS, Torres JR, Cortesia MJ, Murillo J, Losonsky GA, Herrington DA, Stürcher D, Levine MM. *Lancet.* 1989; 334:1415. [PubMed: 2480499]
53. Herzenberg LA, Tokuhisa T. *J Exp Med.* 1982; 155:1730. [PubMed: 6176665]
54. Nakada H, Inoue M, Tanaka N, Numata Y, Kitagawa H, Fukui S, Yamashina I. *Biochem Biophys Res Commun.* 1991; 179:762. [PubMed: 1716888]






Fig. 1.

(a) Anti-Tn IgG titers on days 0, 35 and 89 from mice immunized with glyco-polymer **13** and the anti-Tn IgG titers on day 35 from mice receiving the control polymer **14**. (b) Anti-polymer backbone IgG titers on days 0 and 35 from mice immunized with glyco-polymer **13** and anti-polymer backbone IgG titers on day 35 from mice receiving control polymer **14**. (c) Flow cytometry analysis of Jurkat cell binding by IgG antibodies in sera from representative mice immunized with glycopolymer **13** (orange curve) and control polymer **14** (blue curve). The shaded curve was from pre-immune serum binding with Jurkat cells.



Scheme 1.
Synthesis of polymer 7.



Scheme 2.
Synthesis of glycopolymer **13**.